CANCER-A NOVEL APPROACH THROUGH G-PCRs
Main Article Content
Abstract
Disease and disorder are terms that have been known to the human race for eons but the exact demarcation in the order of their context is very vital as these terms are intermittently used. Discoveries in molecular biology have indeed opened the doors that have broadened the understanding on a range of ailments that has challenged the human race. Investigational studies and intensive research have provided a cohesive understanding on diseases and disorders which in turn deepened the extent of comprehensive analysis. Cancer is one of those clinical manifestations that have been an issue of global health concern. G protein coupled receptors also known as transmembrane receptors or 7 transmembrane receptors correspond to major gene family of human genome. They are known for their biological prominence and their role in a variety of life supporting processes cannot be denied. G protein coupled receptors have been associated with a range of physiological functions and serve as prime targets to over 50 percent of drugs that are employed to counteract several diseases. As a matter of fact the prominence of G protein in accordance with the regulatory processes has been extensively researched and their role in cell multiplication, differentiation, endurance and motility has been validated. Recent studies have substantiated the importance of G-PCRs in tumor growth and have been heavily delved into the aspects of angiogenesis and metastasis. The article emphasizes on cancer and G-PCRs with an attempt to disclose the hidden facets to comprehend GPCRs as potent targets for counteracting cancer.
Downloads
Download data is not yet available.
Article Details
How to Cite
Ranganathan, V. (2021). CANCER-A NOVEL APPROACH THROUGH G-PCRs. Journal of Advanced Scientific Research, 2021(ISTCMS), 01-07. Retrieved from https://sciensage.info/index.php/JASR/article/view/1636
Section
Research Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.